Clinical Trial Update: Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing sequential natalizumab and alemtuzumab therapy in relapsing multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Natalizumab (natalizumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Multiple Sclerosis (MS) | Phase 4 | Status: COMPLETED | Results posted: 2022-02-15